Skip to main content

Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

Clinical Trials Using Anti-CD22 CAR T Cells Preparation

Review the clinical trials studying anti-cd22 car t cells preparation on this list and use the filters to refine the results by age and location. Some clinical trials are held at NCI-Designated Cancer Centers and may be supported by other organizations.

You can find more information about the types and phases of clinical trials and what to expect or use our Steps to Find a Clinical Trial.

Trials 1-14 of 14

Genetically Engineered Cells (CD19x22 CAR T-Cells) for the Treatment of Relapsed or Refractory B-cell Non-Hodgkin Lymphoma
Status: Active
Location: 3 locations
Study Evaluating SC262 in Subjects With r/r Non-Hodgkin's Lymphoma (VIVID)
Status: Active
Location: 2 locations
Genetically Engineered Cells (Anti-CD19/CD20/CD22 CAR T-cells) for the Treatment of Relapsed or Refractory Lymphoid Malignancies
Status: Active
Location: 2 locations
Genetically Engineered Immune Cells (TriCAR-ALL T-Cells) for the Treatment of Recurrent or Refractory CD19, CD20, and/or CD22 Positive B-Cell Acute Lymphoblastic Leukemia
Status: Active
Location: 2 locations
Autologous CD22 Chimeric Antigen Receptor (CAR) T cells following Commercial CD19 CAR T cells for the Treatment of Children and Young Adults with Recurrent or Refractory B Cell Acute Lymphoblastic Leukemia
Status: Active
Location: 2 locations
CD19/CD22 Bicistronic Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory CD19/CD22-expressing B Cell Malignancies
Status: Active
Location: National Institutes of Health Clinical Center, Bethesda, Maryland
CART22-65s and huCART19 CAR T Cells for the Treatment of Relapsed or Refractory B-ALL
Status: Active
Location: Children's Hospital of Philadelphia, Philadelphia, Pennsylvania
Genetically Engineered Cells (CART22 T Cells) for the Treatment of Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia in Pediatric Patients
Status: Active
Location: Children's Hospital of Philadelphia, Philadelphia, Pennsylvania
Phase I Study of Anti-CD22 Chimeric Receptor T Cells in Patients With Relapsed/Refractory Hairy Cell Leukemia and Variant
Status: Active
Location: National Institutes of Health Clinical Center, Bethesda, Maryland
Autologous CD22 Chimeric Antigen Receptor (CAR) T Cells for the Treatment of Recurrent or Refractory B Cell Malignancies or Acute Lymphoblastic Leukemia
Status: Active
Location: Stanford Cancer Institute Palo Alto, Palo Alto, California
CD19/CD22 Chimeric Antigen Receptor T Cell Therapy for Treating Pediatric Patients with Recurrent or Refractory Acute Lymphoblastic Leukemia
Status: Active
Location: Saint Jude Children's Research Hospital, Memphis, Tennessee
Autologous CD22 Chimeric Antigen Receptor (CAR) T Cells for the Treatment of Recurrent or Refractory B Cell Lymphomas
Status: Active
Location: Stanford Cancer Institute Palo Alto, Palo Alto, California
CD19x22 CAR T Cells for the Treatment of Pediatric Patients with Relapsed and/or Refractory B-Cell Acute Lymphoblastic Leukemia
Status: Active
Location: Children's Hospital Colorado, Aurora, Colorado
Genetically Engineered Cells (DuoCAR20.19.22-D95) for the Treatment of Relapsed or Refractory B-Cell Cancers
Status: Active
Location: University of Kansas Cancer Center, Kansas City, Kansas